Losartan Potassium Tablet, Film Coated
Product Images NDC 67296-2225

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Losartan Potassium (NDC 67296-2225). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Redpharm Drug, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Losartanpotassiumfigure1 (Losartanpotassiumfigure1)

A line graph comparing the percentage of patients with the primary endpoint over months of study for Atenolol and Losartan potassium. The x-axis represents study months from 0 to 66, and the y-axis shows the percentage of patients with the primary endpoint from 0% to 16%. Atenolol is shown with a dashed line, Losartan potassium with a solid line. The graph notes an adjusted risk reduction of 13% with a p-value of 0.021.*

FDA Label Image

Losartanpotassiumfigure2 (Losartanpotassiumfigure2)

A line graph comparing the percentage of patients with fatal or non-fatal stroke over study months between Atenolol and Losartan Potassium. The x-axis shows study months from 0 to 66, and the y-axis shows the percentage of patients from 0 to 8%. Two lines represent the treatments, with Atenolol showing a higher stroke incidence rate than Losartan Potassium. The graph includes a note on adjusted risk reduction of 25%, with a p-value of 0.001.*

FDA Label Image

Losartanpotassiumfigure3 (Losartanpotassiumfigure3)

A forest plot comparing event rates and hazard ratios for Losartan Potassium versus Atenolol in a clinical study. The plot shows primary composite outcomes and stroke (fatal/non-fatal) events across patient subgroups defined by age, gender, race, ISH, diabetes status, and history of cardiovascular disease. Hazard ratios with 95% confidence intervals indicate comparative results favoring either Losartan Potassium or Atenolol.*

FDA Label Image

Losartanpotassiumfigure4 (Losartanpotassiumfigure4)

A line graph comparing the percentage of patients with an event over 48 months for Losartan Potassium versus placebo. The graph shows a risk reduction of 16.1% with a p-value of 0.022, with solid and dashed lines representing Losartan Potassium and placebo, respectively.*

FDA Label Image

Losartanpotassiumlabel100mg90s (Losartanpotassiumlabel100mg90s)

Label for Losartan Potassium Tablets USP 100 mg, supplied in a package of 90 tablets. The label indicates the product is manufactured by Hetero Labs Limited in India and made for Northstar Rx LLC, Memphis, TN. It includes storage instructions, a barcode, and a warning to keep out of reach of children.*

FDA Label Image

Losartanpotassiumlabel25mg90s (Losartanpotassiumlabel25mg90s)

Label for Losartan Potassium Tablets USP, 25 mg strength, containing 90 tablets. The label features the NDC 72603-340-01, the NorthStar branding, storage instructions, a warning to keep out of reach of children, and manufacturing details noting production by Hetero Labs Limited in India for Northstar Rx LLC, Memphis, TN.*

FDA Label Image

Losartanpotassiumlabel50mg90s (Losartanpotassiumlabel50mg90s)

Label for Losartan Potassium Tablets USP 50 mg, containing 90 tablets. The label includes dosage information, storage instructions, warnings, and manufacturing details. It is marked with the NorthStar logo and indicates the product is manufactured in India for Northstar Rx LLC.*

FDA Label Image

Losartanpotassiumstructure (Losartanpotassiumstructure)

Chemical structure of Losartan Potassium, showing its molecular components including chlorine, hydroxyl group, butyl side chain, and potassium ion associated with the triazole ring.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.